RxDoctor Payments Data

Juanly Rodriguez Velez, MD

Nephrology · Sumter, SCNPI 1740708221

Payments from drug & device makers

$959in general payments, 2019–2025

Across 35 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$132
  • Amgen$124
  • Aurinia Pharma U.S., Inc.$117
  • Novo Nordisk$99
  • GSK$86
  • Boehringer Ingelheim$83
  • plus $319 from 9 others

What the payments were for

  • Food & beverage$90995%
  • Education$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 35th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$187,567
Medicare patients
311
Services billed
3,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol133$100,957
JardianceEmpagliflozin80$70,622
KerendiaFinerenone88$58,566
LokelmaSodium Zirconium Cyclosilicate41$37,034
JanuviaSitagliptin Phosphate31$29,481
OzempicSemaglutide26$24,341
MounjaroTirzepatide20$22,445
EntrestoSacubitril/Valsartan17$13,923
LinzessLinaclotide17$11,160
TrulicityDulaglutide12$10,935
EliquisApixaban13$9,477
Cinacalcet Hcl15$4,787
Sevelamer Carbonate22$4,613
Losartan Potassium154$1,255
Calcitriol133$1,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$65$137,991174 claims
Boehringer IngelheimJardiance$83$70,62280 claims
BayerKerendia$48$58,56688 claims
Novo NordiskOzempic$99$24,34126 claims
NovartisEntresto$35$13,92317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →